Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Nephrology · Fanconi Renotubular Syndrome Type 2

The Biology and Diagnosis of FRTS2

At a Glance

FRTS2 usually occurs when disease-causing changes affect both copies of the SLC34A1 gene, disrupting the kidney’s ability to reclaim phosphate. Diagnosis combines genetic testing with low blood phosphate, kidney phosphate loss, mineral findings, and ultrasound monitoring for calcium deposits.

The diagnosis of Fanconi Renotubular Syndrome Type 2 (FRTS2) is a puzzle that doctors piece together using genetics, blood chemistry, and imaging. At its core, the condition is caused by a genetic alteration in the kidney’s filtration system, which allows vital nutrients—primarily phosphate—to leak out of the body [1][2].

The Biological Mechanism: A Faulty Transporter

Every person has two copies of the SLC34A1 gene. This gene provides the instructions for building a protein called NaPi-IIa [1]. Think of NaPi-IIa as a specialized transporter located in the proximal tubule (the first section of the kidney’s filtering unit) [3].

In a healthy kidney, this transporter captures phosphate from the urine and pulls it back into the bloodstream. In FRTS2, pathogenic variants (mutations) in the SLC34A1 gene cause these transporters to be misshapen or dysfunctional [4][5]. Because they cannot do their job, phosphate is continuously lost in the urine (phosphate wasting), leading to a chain reaction of mineral imbalances [2].

The Role of Genetics: Biallelic vs. Heterozygous

The severity of the condition depends on how the gene variants are inherited. A genetic counselor is highly recommended to interpret your specific results.

  • Individuals with Biallelic Variants: FRTS2 typically occurs when a person inherits two pathogenic variants in the SLC34A1 gene—one from each parent (autosomal recessive) [6][7]. This presentation generally leads to the classic symptoms of infantile hypercalcemia, poor growth, and significant phosphate wasting [7].
  • Heterozygous Individuals: If only one copy of the gene is altered, a person is heterozygous. While they do not have classic recessive FRTS2, having a single specific pathogenic SLC34A1 variant can sometimes cause issues, such as elevated urine calcium, kidney stones, or bone health concerns later in life [8][9]. However, the exact impact depends heavily on the specific variant’s classification.

The Diagnostic Workup: Key Tests

To investigate FRTS2, doctors look for a specific “signature” in blood and urine tests:

  • Serum Phosphate: Usually low (hypophosphatemia) because the kidneys are losing it [2].
  • TmP/GFR: This is a specialized calculation based on appropriately paired blood and urine samples. It measures how well the kidneys are reabsorbing phosphate. A low TmP/GFR strongly supports renal phosphate wasting [2][10].
  • Calcium Levels: Serum calcium may be high (hypercalcemia) in infants, while urine calcium (hypercalciuria) is often high in both children and adults [6][11].
  • PTH and 1,25-dihydroxyvitamin D: In FRTS2, the body often produces too much of the active form of Vitamin D (1,25-dihydroxyvitamin D). This overproduction suppresses the parathyroid hormone (PTH) [6][2]. Finding high active Vitamin D alongside a very low PTH is a major clue that prompts genetic testing [6].

Imaging and Monitoring

A renal ultrasound is routinely ordered to look for nephrocalcinosis, which is a buildup of calcium deposits within the kidney tissue [12][11]. While nephrocalcinosis is highly common in FRTS2 (one small study of 11 children found it in 100% of them at diagnosis), it is considered a complication to monitor, rather than a strict requirement for diagnosis [11]. The absence of kidney calcifications does not rule out the disease.

Diagnosis Checklist

Because FRTS2 mimics other conditions, a complete diagnostic evaluation typically includes:

  1. Genetic Confirmation: Identification of pathogenic variants in the SLC34A1 gene [6].
  2. Biochemical Signature: Evidence of low blood phosphate, low TmP/GFR, and elevated active Vitamin D [2][7].
  3. Exclusion of Mimics: Proper medical evaluation to ensure that other genes (like CYP24A1 for infantile hypercalcemia) or acquired factors are not the true cause [12][13].
  4. Imaging Evidence: An ultrasound is used to monitor for calcium deposits or kidney stones [11].

Common questions in this guide

What causes Fanconi renotubular syndrome type 2?
FRTS2 usually results when a person inherits disease-causing changes in both copies of the SLC34A1 gene, one from each parent. These changes impair a phosphate transporter in the kidney’s proximal tubule, so phosphate is lost in urine.
Which test results can point to FRTS2?
Common clues may include low blood phosphate, a low TmP/GFR, high urine calcium, and increased active vitamin D with suppressed PTH. Doctors combine these findings with genetic testing because no single blood or urine result proves FRTS2.
Does having one SLC34A1 variant mean I have FRTS2?
Classic recessive FRTS2 usually requires disease-causing variants in both copies of SLC34A1. A person with one altered copy may not have classic FRTS2 but can have high urine calcium, kidney stones, or bone health concerns with certain variants, so a genetics professional should interpret the result.
Why is a kidney ultrasound used when evaluating FRTS2?
A renal ultrasound can look for nephrocalcinosis, meaning calcium deposits in kidney tissue, and for kidney stones. Nephrocalcinosis is common in reported children with FRTS2, but a normal ultrasound does not rule out the condition.
How is FRTS2 distinguished from similar disorders?
Diagnosis typically combines disease-causing SLC34A1 findings with evidence of kidney phosphate wasting and the characteristic mineral pattern. Doctors may also evaluate other causes of infantile high calcium, including CYP24A1-related disease, before confirming the diagnosis.

Get notified when new evidence is published on Fanconi renotubular syndrome 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review.

    Walker E, Hayes W, Bockenhauer D

    Best practice & research. Clinical endocrinology & metabolism 2024; (38(2)):101843 doi:10.1016/j.beem.2023.101843.

    PMID: 38042745
  2. 2

    Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia.

    Schlingmann KP, Ruminska J, Kaufmann M, et al.

    Journal of the American Society of Nephrology : JASN 2016; (27(2)):604-14 doi:10.1681/ASN.2014101025.

    PMID: 26047794
  3. 3

    Fibroblast growth factor 23 leads to endolysosomal routing of the renal phosphate cotransporters NaPi-IIa and NaPi-IIc in vivo.

    Küng CJ, Haykir B, Schnitzbauer U, et al.

    American journal of physiology. Renal physiology 2021; (321(6)):F785-F798 doi:10.1152/ajprenal.00250.2021.

    PMID: 34719948
  4. 4

    Clinical Heterogeneity and Phenotypic Expansion of NaPi-IIa-Associated Disease.

    Demir K, Yildiz M, Bahat H, et al.

    The Journal of clinical endocrinology and metabolism 2017; (102(12)):4604-4614 doi:10.1210/jc.2017-01592.

    PMID: 29029121
  5. 5

    Clinical, biochemical, and pathophysiological analysis of SLC34A1 mutations.

    Fearn A, Allison B, Rice SJ, et al.

    Physiological reports 2018; (6(12)):e13715 doi:10.14814/phy2.13715.

    PMID: 29924459
  6. 6

    Identification of a Novel Homozygous SLC34A1 Missense Mutation and a Heterozygous SLC34A3 Deletion in an Infant with Nephrocalcinosis, Failure to Thrive, and Hypercalcemia.

    Mura-Escorche G, García-Suarez LC, Lebredo-Álvarez I, et al.

    International journal of molecular sciences 2025; (26(17)) doi:10.3390/ijms26178541.

    PMID: 40943461
  7. 7

    Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2c.

    Brunkhorst M, Brunkhorst L, Martens H, et al.

    Kidney international 2025; (107(1)):116-129 doi:10.1016/j.kint.2024.08.035.

    PMID: 39461557
  8. 8

    A Novel Heterozygous Mutation c.1627G>T (p.Gly543Cys) in the SLC34A1 Gene in a Male Patient with Recurrent Nephrolithiasis and Early Onset Osteopenia: A Case Report.

    Giusti F, Marini F, Al-Alwani H, et al.

    International journal of molecular sciences 2023; (24(24)) doi:10.3390/ijms242417289.

    PMID: 38139117
  9. 9

    Clinical aspects of the phosphate transporters NaPi-IIa and NaPi-IIb: mutations and disease associations.

    Lederer E, Wagner CA

    Pflugers Archiv : European journal of physiology 2019; (471(1)):137-148 doi:10.1007/s00424-018-2246-5.

    PMID: 30542787
  10. 10

    Evidence for a role of PDZ domain-containing proteins to mediate hypophosphatemia in calcium stone formers.

    Bergsland KJ, Coe FL, Parks JH, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018; (33(5)):759-770 doi:10.1093/ndt/gfx284.

    PMID: 29126251
  11. 11

    Targeting Hypercalciuria in SLC34A1-Related Disorders: Impact of Oral Phosphate Therapy and Novel Genetic Insights in Pediatric Case Series.

    Turan I, Atar M, Eltan M, et al.

    Calcified tissue international 2026; (117(1)):10 doi:10.1007/s00223-025-01462-x.

    PMID: 41543768
  12. 12

    Prenatal hyperechogenic kidneys in three cases of infantile hypercalcemia associated with SLC34A1 mutations.

    Hureaux M, Molin A, Jay N, et al.

    Pediatric nephrology (Berlin, Germany) 2018; (33(10)):1723-1729 doi:10.1007/s00467-018-3998-z.

    PMID: 29959532
  13. 13

    Cystinosis: a review.

    Elmonem MA, Veys KR, Soliman NA, et al.

    Orphanet journal of rare diseases 2016; (11()):47 doi:10.1186/s13023-016-0426-y.

    PMID: 27102039

This page is for informational purposes only and does not constitute medical advice. A nephrologist and genetic counselor should interpret your SLC34A1 results, laboratory values, and imaging in the context of your health.